OncoCyte (NASDAQ: OCX) is a molecular diagnostics company focused on the development and commercialization of non-invasive tests for the early detection and management of cancer. Founded in 2014 and headquartered in Irvine, California, the company leverages proprietary biomarker panels and advanced analytical platforms to deliver blood-based assays aimed at reducing unnecessary invasive procedures and improving patient outcomes. OncoCyte’s lead product candidate, DetermaVu™, is designed as a rule-out test for indeterminate pulmonary nodules identified through CT imaging, helping physicians distinguish benign lesions from those warranting further intervention.
In addition to its lung cancer test, OncoCyte is advancing a pipeline of oncology assays targeting ovarian and other solid-tumor cancers. These programs utilize circulating cell-free DNA (cfDNA) methylation patterns and transcriptomic signatures to detect malignancies at an earlier stage than traditional diagnostic methods. Clinical validation studies for these assays are ongoing, with the goal of securing regulatory clearance and commercial reimbursement coverage in major markets.
OncoCyte serves healthcare providers, imaging centers and pathology laboratories across the United States, and is exploring collaborations to extend its technology platform into Europe and Asia. The company has built partnerships with leading academic institutions and contract research organizations to support its clinical trials and regulatory filings. Manufacturing and laboratory operations are conducted at its state-of-the-art facilities in Southern California, ensuring quality control and scalability as the product line expands.
The management team is led by Chief Executive Officer Nathan J. Bellis, whose background includes senior roles in molecular diagnostics and precision medicine. OncoCyte’s board and scientific advisory committees feature experts in oncology, biostatistics and health economics, providing strategic guidance on clinical development, regulatory strategy and market access. As OncoCyte advances its portfolio, it aims to offer physicians actionable tools that facilitate earlier cancer detection and personalized care pathways.
AI Generated. May Contain Errors.
